SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (Level42)
Key facts
- Who runs it
- The Geneva Foundation
- Where
- Fort Sam Houston, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 300 people enrolled
- Started
- 15 May 2023
- Ended
- 30 Mar 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
- Record updated
- 15 July 2026
Who can take part
- Age
- 18 years to 89 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Asymptomatic and symptomatic individuals 18 years and older
- Receiving standard COVID-19, Flu, and/or RSV screening and testing at BAMC
- Do not have to be diagnosed with SARS-CoV-19 (COVID-19), Flu, and/or RSV but only be screened
- English Speaking
Who cannot take part
- Any individual under age of 18
- Anyone unable to comply (or be assisted) with study procedures
- Anyone not able to provide temperature thermal scan, and/or 3-minute vibroacoustic scan
Where in United States
- Brooke Army Medical CenterFort Sam Houston, United States
About the trial
What the trial wants to find out
The goal of this observational study is to evaluate new non-invasive passive surveillance technologies, Level 42 AI imPulse™ Una and TOR devices for the detection of COVID-19, Flu, and/or RSV in asymptomatic and symptomatic individuals over age of 18 undergoing COVID-19, Flu, and/or RSV screening and testing at BAMC Ft Sam Houston, TX; with and without COVID-19, Flu, and/or RSV.
Read full original descriptionShow less
The hypotheses are:
(H1) The imPulseTM Una and the imPulseTM TOR e-stethoscopes have at least a similar discriminative and detection ability among symptomatic and asymptomatic COVID-19 carrier versus those not infected compared to gold standard RT-PCR. We will operationalize and deploy both the imPulseTM Una and imPulseTM TOR e-stethoscope into DoD use-cases and compare their usability between the devices.
(H2) Identify if the imPulseTM Una and the imPulseTM TOR e-stethoscopes have at least a similar discriminative and detection ability among symptomatic and asymptomatic Respiratory Syncytial Virus (RSV), Influenza and Long COVID carriers versus those not infected compared to gold standard Rapid RSV and Flu Antigen Tests, or RT-PCR and molecular assays. We will operationalize and deploy both the imPulseTM Una and imPulseTM TOR e-stethoscope into DoD use-cases and compare their captured traces in the early identification of disease/illness analyzed by the devices built in algorithms.
(H3) In the mid to long-term, this approach will also be explored as a diagnostic system to explore pursue the physical (structural and mechanical) properties of cells and tissues that maintain normal cell behavior (motility, growth, apoptosis), and the critical importance of the ability of cells to sense and respond to mechanical stresses, which will be operationally critical for assessment of both traumatic and unconventional exposures in austere environments.
Participants will:
* Be consented; * Be screened for COVID-19, Flu, and/or RSV symptoms according to BAMC's current screening procedures; * Have study data collected; * Complete a symptoms questionnaire; * imPulseTM Una and TOR e-stethoscopes examination will be conducted; * Participants will be compensated for completing all study requirements. (Active-Duty personnel must complete the study procedures while off-duty in order to receive compensation.)
The 2 groups in the trial
- COVID-19, Flu, and/or RSV positive patients
Participants screened with known COVID-19, Flu, and/or RSV positive test results obtained within 48hrs of recruitment.
Treatment: imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
- COVID-19, Flu, and/or RSV negative patients
Participants screened with known COVID-19, Flu, and/or RSV negative test results obtained within 48hrs of recruitment.
Treatment: imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies
- Record updated
- 15 July 2026